Inside Maine’s Medicine Cabinet. Inside Maine’s Medicine Cabinet: Analysis of the Maine Prescription Monitoring Program, 2010-2014 Christina Holt, MD,

Slides:



Advertisements
Similar presentations
Trend in Prescription Drug Abuse In 2004, 19.1 million Americans were current illicit drug users (7.9% of the U.S. population) 1 In 2004, 19.1 million.
Advertisements

Heather Stewart Doctor of Pharmacy Candidate, 2014 Generation Rx Co-Chair, APhA-ASP Stevan Gressitt, M.D. Founding Director, International Institute for.
Diversion Alert. Prescription Monitoring Program Trends among Individuals Arrested in Maine for Trafficking Prescription Drugs, 2014 Christina Holt, MD,
Prescription Opioid Overdose & Misuse in Oregon Mel Kohn, MD MPH Public Health Director and State Public Health Officer Oregon Health Authority Oregon.
CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.
A Common Cause of Poisoning
® Introduction Low Back Pain and Physical Function Among Different Ethnicities Adelle A Safo, Sarah Holder DO, Sandra Burge PhD The University of Texas.
OVERDOSE SOLUTIONS 2013 OVERDOSE DATA FOR ALLEGHENY COUNTY Jennifer Janssen Manager Toxicology Laboratory Allegheny County Office of the Medical Examiner.
Rx for Drug-Seeking Patients in the ED The Monterey County Prescribe Safe Initiative 1.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
2008 International Symposium on Pharmaceuticals in the Home PMP/TDS Update Debra Brucker, M.P.A., Ph.D. Daniel Eccher, M.P.H. Maine Office of Substance.
Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.
Texas Demographic Characteristics and Trends Texas Association of Mutual Insurance Companies October 7, 2010 Round Rock, TX 1.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Epidemiology of Benzodiazepine Prescribing and Use Gerry & Marci’s Story 4 nd Annual Benzodiazepine Conference Portland, Maine 2006.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
® Introduction The Skinny on Obesity in Texas: BMI in Texas Family Medicine Clinics Kristin M. Yeung, Ramin Poursani, MD, Sandra K. Burge, PhD The University.
1 Adolescent Mental Health: Key Data Indicators Gwendolyn J. Adam, Ph.D., L.C.S.W. Assistant Professor - Department of Pediatrics Section of Adolescent.
1 Health Care Cost Drivers: Hospital and Other Health Expenditures—Descriptive Overview April 28, 2011.
The South Florida Report January 2013 National Institute on Drug Abuse Community Epidemiology Work Group James N. Hall Report # 56 Center for Applied Research.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Texas Demographics and Sustainability Texas State University November 17, 2010 San Marcos, TX 1.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Understanding Health Disparities in Texas Maureen Rubin, Ph.D., MSW Assistant Professor Department of Social Work University of Texas at San Antonio Nazrul.
Snapshot of IMS LifeLink Claims Database 10% Random Sample
Disparities in the Adequacy of Depression Treatment in the United States Jeffrey S. Harman, Ph.D. University of Florida Mark J. Edlund, M.D., Ph.D. John.
Vulnerability to Opioid Withdrawal Symptoms Among Chronic Low Back Pain Patients Subjects. In 2008, student research assistants consented and enrolled.
March 2004 Prescription Drug Abuse in the United States.
Component 1: Introduction to Health Care and Public Health in the U.S. Unit 3: Delivering Healthcare (Part 2) Outpatient Care (Retail, Urgent and Emergency.
Introduction to Healthcare and Public Health in the US Delivering Healthcare (Part 2) Lecture c This material (Comp1_Unit3c) was developed by Oregon Health.
Component 1: Introduction to Health Care and Public Health in the U.S. Unit 3: Delivering Healthcare (Part 2) Lecture 3 This material was developed by.
For Pain or Not for Pain: Methadone Madness
Oral Health in Maine: Facts & Figures, August 2005 Judith A. Feinstein, MSPH Director, Maine Oral Health Program ME Center for Disease Control & Prevention.
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
1 An Economic and Policy Analysis of the Market for Methylphenidate and Amphetamine Rick Mayes University of Richmond Farasat Bokhari University of California,
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid.
Source: John Jay College calculations of national arrest estimates using data from Crime in the United States, 1980 through Washington, DC: Federal.
® Changes in Opioid Use Over One Year in Patients with Chronic Low Back Pain Alejandra Garza, Gerald Kizerian, PhD, Sandra Burge, PhD The University of.
Substance Use among Older Adults (Age 50+): Current Prevalence and Future Expectations Presented by Joe Gfroerer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.
The Role of Residential Segregation in Disparity Research: A Case Example of ADHD Diagnosis and Treatment Dinci Pennap, MPH, 1 Mehmet Burcu, MS, 1 Daniel.
Finding a Predictive Model for Post-Hospitalization Adverse Events Henry Carretta 1, PhD, MPH; Katrina McAfee 1,2, MS; Dennis Tsilimingras 1,3, MD, MPH.
Jennifer R. Havens, PhD, MPH Associate Professor
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
The Latest Prescription Trends for Controlled Prescription Drugs
1 Prescribing Pain Medication – Guidelines for the Emergency Department April 22, 2012 Jennifer Sabel, PhD.
Health Literacy: Helping Your Patients Understand and Ethical Dilemmas in Geriatric Care.
Summary Report and Recommendations on Prescription Drugs: Misuse, Abuse and Dependency Presentation for the County Alcohol and Drug Program Administrators’
1 READY BY 21 TASKFORCE Harford County Department of Community Services Local Management Board Health Benchmark December 7, 2010.
Medstat MercuryMD Micromedex PDR Solucient Substance abuse medications: Trends and prescribing patterns by physician specialty November 5, 2007 American.
Drug Enforcement Administration Greater Kansas City Chapter American Society for Pain Management Nursing October 24, 2015 Judy R. Williams Group Supervisor.
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
Positive predictive value (PPV) associated with statins from EHR prescribing data relative to pharmacy dispensing data in the OptumLabs™ Data Warehouse.
Mental Health and Substance Abuse Prescription Drug Spending Trends: Medicaid and Privately Insured Populations American Public Health Association Annual.
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
Medication Assisted Treatment
Brian C. Martin, Ph.D., MBA East Tennessee State University
OPIOID EPIDEMIC.
American Public Health Association Annual Meeting November 5, 2007
San Francisco County OBOT Pilot: Pharmacy Aspects
The Scope of the Problem
Overlapping Opioid and Benzodiazepines in Delaware: A Baseline Report to inform Delaware DOJ 9-Point Plan (September 5, 2017) Report prepared by: Tammy.
Prescription Drug Monitoring Program Facts, Figures, and Trends 3rd Quarter 2017 North Dakota Board of Pharmacy Kathy Zahn, CPhT, PDMP Program Administrator.
ROOM project Addressing the Opioid Epidemic in the U.P.
Controlled substance compliance
Brain and Behavior Substance Abuse
Prescription Drug Monitoring Program
Prescription Drug Monitoring Program
Presentation transcript:

Inside Maine’s Medicine Cabinet

Inside Maine’s Medicine Cabinet: Analysis of the Maine Prescription Monitoring Program, Christina Holt, MD, MSc 1, Kenneth McCall, PharmD 2, Stephanie Nichols, PharmD, BCPS, BCPP 3, Leslie Ochs, PhD, PharmD, BCPS 2, BCPS, Gary Cattabriga, BA 4, Chunhao Tu, PhD 2 1.Maine Medical Center, Department of Family Medicine, Portland, ME 2.College of Pharmacy, University of New England, Portland, ME 3.School of Pharmacy, Husson University, Bangor, ME 4.Center for Community & Public Health, University of New England, Portland, ME

Outline Prescribing Trends: Maine PMP, Opioids – Buprenorphine Sedatives – Benzodiazepines Stimulants

Limitations The Maine VA System began reporting to the Maine PMP on 10/30/2014. Controlled prescriptions dispensed in other New England states are not included in the Maine PMP. Maine PMP prescription and recipient counts may include non-Maine residents. Methadone Clinics and Opioid Treatment Programs are exempt by federal regulations (42 CFR Part 2) from submitting data to the PMP. The administration of a drug in a clinic, emergency room, or other outpatient facility is not required to be reported to the PMP.

Number of Controlled Prescriptions (x1,000) : Maine PMP, ‘Sedatives’ includes benzodiazepines and ‘z’ hypnotic drugs such as zolpidem.

Maine PMP 2014: The Big Picture million dosage units (e.g., tablets, capsules, patches, etc.) of controlled prescription drugs were prescribed and dispensed in Maine in million days-supply of controlled prescription drugs were prescribed and dispensed in Maine which is enough to medicate every man, woman and child around-the-clock for more than a month.

OPIOIDS

Number of Opioid Prescriptions (x1,000) : Maine PMP, For comparative purposes, the Maine population estimated by the US Census Bureau: 2006 = 1,324,000; 2010 = 1,328,000; 2014 = 1,330,000

Number of Opioid Prescriptions (x1000) by Product: Maine PMP, 2010 & 2014 *Hydrocodone reclassified to DEA C-II in 2014, Tramadol reclassified to DEA C-IV in 2014, Propoxyphene withdrawn from US market in

Trends in Number of Prescriptions of the Top 3 Opioids in Maine PMP, *Hydrocodone reclassified from DEA C-III to C-II in 2014

Number of Opioid Prescriptions per Capita 1 by County: Maine PMP, 2014 COUNTYRXsRXs/CAPITA Androscoggin,ME108, Aroostook,ME63, Cumberland,ME*219, * Franklin,ME25, Hancock,ME48, Kennebec,ME132, Knox,ME43, Lincoln,ME35, Oxford,ME58, Penobscot,ME139, Piscataquis,ME16, Sagadahoc,ME30, Somerset,ME55, Waldo,ME37, Washington,ME34, York,ME171, MAINE TOTAL1,222, *This value is furthest from the rest, but not a significant outlier (P>0.05) 1. Maine County Population, 2010, US Census Bureau

Prescription Opioids: Key Findings In Maine, 1.22 million opioid prescriptions were dispensed for 291,000 individuals in Opioid prescribing peaked in 2010 at 1.31 million prescriptions annually. The peak was followed by a decline in opioid prescriptions from 2010 to 2013 and subsequently an increase in The recent increase may be related to the reclassification of Tramadal to DEA CIV in 2014 and the addition of Maine VA reporting in Hydrocodone containing products were the most common opioid prescribed in However, the recent reclassification of hydrocodone to DEA CII will likely affect future prescribing trends. While hydrocodone and oxycodone prescriptions consistently declined from 2010 to 2014, buprenorphine prescriptions have increased more than any other opioid in the same timeframe. Counties with the highest opioid prescriptions per capita include: Kennebec, Knox, Washington, and Somerset

Buprenorphine

Number of Buprenorphine Prescriptions (x100) and Recipients (x10) per year: Maine PMP From 2010 to 2014, the number of buprenorphine prescriptions, and recipients have increased by 65% and 48%, respectively. 317 buprenorphine prescribers in 2014 and 344 in 2015 (up only 9%) 214/344 (62%) wrote tx prescriptions 214/344 (62%) wrote tx prescriptions

Key Findings: Buprenorphine 156,088 buprenorphine prescriptions were dispensed for 13,050 individuals in Maine in 2014 The number of buprenorphine prescriptions and recipients has increased from 2010 to 2014 by 65% and 48% respectively, but the number of prescribers only increased 9% from 2014 – Buprenorphine prescribers are unequally distributed by county with some counties experiencing a decline in prescribers (Franklin, Hancock, Washington, York, Piscataquis, and Knox). Most physicians in Maine who prescribe buprenorphine are currently treating under 100 patients (mean = 41). However, the 2006 DATA amendment allows physicians to treat up to 100 patients after the first year of treating 30.

SEDATIVES

Number of Sedative Prescriptions (x1,000) : Maine PMP, For comparative purposes, the Maine population estimated by the US Census Bureau: 2006 = 1,324,000; 2010 = 1,328,000; 2014 = 1,330,000

Number of Sedative Prescriptions (x1000) by Product: Maine PMP, 2014

Number of Benzodiazepine Prescriptions per Capita 1 by County: Maine PMP, 2014 COUNTYRXsRXs/CAPITA Androscoggin,ME*42, * Aroostook,ME33, Cumberland,ME143, Franklin,ME*11, * Hancock,ME26, Kennebec,ME62, Knox,ME22, Lincoln,ME17, Oxford,ME25, Penobscot,ME73, Piscataquis,ME8, Sagadahoc,ME17, Somerset,ME26, Waldo,ME18, Washington,ME18, York,ME*104, * MAINE TOTAL651, *These values are furthest from the rest, but are not significant outliers (P>0.05) 1. Maine County Population, 2010, US Census Bureau

Number of benzodiazepine prescriptions per year (x1,000) stratified by age and gender, Maine PMP AGE & GENDER years Female years Female years Female TOTAL* For comparison, Maine Population according to 2010 US Census Data: Total population 1,328,361; 0-19 years 310,959; years 716,662; 60+ years 300,740 Female 678,305; 0-19 years 151,075; years 363,319; 60+ years 163,911 2.Data Extraction *including those categorized as unknown age

Number of individuals (x1,000) who received a benzodiazepine prescription stratified by age and gender, Maine PMP AGE & GENDER years Female years Female years Female TOTAL* For comparison, Maine Population according to 2010 US Census Data: Total population 1,328,361; 0-19 years 310,959; years 716,662; 60+ years 300,740 Female 678,305; 0-19 years 151,075; years 363,319; 60+ years 163,911 2.Data Extraction *Including those categorized as unknown age.

Proportion of Maine population who received a benzodiazepine prescription stratified by age, Maine PMP * * Maine PMP Recipient and Rx counts may include non-Maine residents For comparative purposes, the Maine population estimated by the US Census Bureau: 2010 = 1,328,000; 2014 = 1,330,000

Proportion of Maine population who received a benzodiazepine prescription stratified by age and gender, Maine PMP 2014* *Maine PMP Recipient and Rx counts may include non-Maine residents

Prescription Sedatives: Key Findings In Maine, 677,000 benzodiazepine and 179,000 “z drug” prescriptions were dispensed for greater than 155,000 individuals in Sedative prescriptions peaked in 2010 at 904,000 Benzodiazepine prescribing rates are highest among adults 60 years and older and especially highest among women in that age range Among adults age 60 years and older in Maine, approximately 1 in 5 received one or more benzodiazepine prescriptions in There may be an upward trend in the proportion of adults 60 years and older in Maine who are receiving benzodiazepine prescriptions (2011 – 18% vs 2014 – 21%) despite cautions regarding their use in older adults.

STIMULANTS

Number of Stimulant Prescriptions (x1,000) : Maine PMP, For comparative purposes, the Maine population estimated by the US Census Bureau: 2006 = 1,324,000; 2010 = 1,328,000; 2014 = 1,330,000

Number of Stimulant Prescriptions (x1000) by Product: Maine PMP, 2014

Overall Trends in Stimulant Prescriptions: Maine PMP,

Number of Stimulant Prescriptions per Capita 1 by County: Maine PMP, 2014 COUNTYRXsRXs/CAPITA Androscoggin,ME 25, Aroostook,ME 14, Cumberland,ME* 122, * Franklin,ME 5, Hancock,ME 12, Kennebec,ME 40, Knox,ME 9, Lincoln,ME 6, Oxford,ME 7, Penobscot,ME* 68, * Piscataquis,ME 4, Sagadahoc,ME 1, Somerset,ME 4, Waldo,ME 5, Washington,ME 5, York,ME 52, MAINE TOTAL 387, *These values are furthest from the rest, but are not significant outliers (P>0.05) 1. Maine County Population, 2010, US Census Bureau

Number of stimulant prescriptions (x1,000) per year stratified by age, Maine PMP AGE RELATIVE INCREASE 0 – % % % 1.For comparison, Maine Population according to 2010 US Census Data: Total population 1,328,361; 0-19 years 310,959; years 716,662; 60+ years 300,740 Female 678,305; 0-19 years 151,075; years 363,319; 60+ years 163,911 2.Data Extraction

Number of individuals (x1,000) who received a stimulant prescription stratified by age, Maine PMP For comparison, Maine Population according to 2010 US Census Data: Total population 1,328,361; 0-19 years 310,959; years 716,662; 60+ years 300,740 Female 678,305; 0-19 years 151,075; years 363,319; 60+ years 163,911 2.Data Extraction AGE RELATIVE INCREASE % % %

Prescription Stimulants: Key Findings In Maine, 395,000 stimulant prescriptions were dispensed for 57,800 individuals in Stimulants are the fastest growing category in the Maine PMP with a 91% increase in annual prescriptions from 2006 to All age categories experienced an increase in the number of stimulant prescriptions from 2010 to 2014 with the highest rate of increase among adults 30 years and older. Over 11,000 more people were prescribed stimulants in 2014 versus 2010 with the highest rate of increase among adults 30 years and older.

Acknowledgments: Office of Substance Abuse, PMP Program Coordinator: John Liposky Professors Brian Piper, PhD and Sarah Martin, PhD, Husson University School of Pharmacy. Funding from AAFP